基于干细胞的肝硬化学治疗的当前观点。
Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.
机构信息
Department of Oral Anatomy, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Republic of Korea.
Department of Preventive and Social Dentistry, School of Dentistry, Seoul National University and Dental Research Institute, Seoul, Republic of Korea.
出版信息
Can J Gastroenterol Hepatol. 2018 Jan 29;2018:4197857. doi: 10.1155/2018/4197857. eCollection 2018.
Abstract
Liver cirrhosis is a major cause of mortality and a common end of various progressive liver diseases. Since the effective treatment is currently limited to liver transplantation, stem cell-based therapy as an alternative has attracted interest due to promising results from preclinical and clinical studies. However, there is still much to be understood regarding the precise mechanisms of action. A number of stem cells from different origins have been employed for hepatic regeneration with different degrees of success. The present review presents a synopsis of stem cell research for the treatment of patients with liver cirrhosis according to the stem cell type. Clinical trials to date are summarized briefly. Finally, issues to be resolved and future perspectives are discussed with regard to clinical applications.
摘要
肝硬化是死亡的主要原因，也是各种进行性肝病的常见终末期病变。由于目前有效的治疗方法仅限于肝移植，因此基于干细胞的治疗方法作为一种替代方法引起了人们的兴趣，因为临床前和临床研究结果令人鼓舞。然而，对于确切的作用机制仍有许多需要了解。已经使用了来自不同来源的多种干细胞来进行肝再生，其成功率也有所不同。本综述根据干细胞类型概述了用于治疗肝硬化患者的干细胞研究。简要总结了迄今为止的临床试验。最后，讨论了临床应用中需要解决的问题和未来展望。
相似文献
1
Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.基于干细胞的肝硬化学治疗的当前观点。
Can J Gastroenterol Hepatol. 2018 Jan 29;2018:4197857. doi: 10.1155/2018/4197857. eCollection 2018.
2
Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis.自体间充质干细胞移植治疗肝硬化患者的疗效
Turk J Gastroenterol. 2015 May;26(3):244-50. doi: 10.5152/tjg.2015.0074.
3
The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis.骨髓间充质干细胞对肝硬化的治疗潜力。
Stem Cell Res. 2009 Jan;2(1):16-25. doi: 10.1016/j.scr.2008.07.005. Epub 2008 Aug 6.
4
Transplantation with GXHPC1 for Liver Cirrhosis: Phase 1 Trial.应用 GXHPC1 治疗肝硬化：1 期临床试验。
Cell Transplant. 2019 Dec;28(1_suppl):100S-111S. doi: 10.1177/0963689719884885. Epub 2019 Nov 14.
5
Stem cells and hepatic cirrhosis.干细胞与肝硬变。
Panminerva Med. 2010 Jun;52(2):149-65.
6
[Mesenchymal stem cells as perspective method of fibrosis/cirrhosis treatment].[间充质干细胞作为纤维化/肝硬化治疗的前瞻性方法]
Eksp Klin Gastroenterol. 2013(12):3-7.
7
Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.间充质干细胞治疗肝纤维化的应用：现状与未来展望
World J Gastroenterol. 2015 Jan 21;21(3):742-58. doi: 10.3748/wjg.v21.i3.742.
8
Bone marrow derived stem cells for the treatment of end-stage liver disease.用于治疗终末期肝病的骨髓源干细胞。
World J Gastroenterol. 2014 Jul 21;20(27):9098-105. doi: 10.3748/wjg.v20.i27.9098.
9
Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis.间充质干细胞：治疗肝硬变的潜在应用。
Stem Cell Res Ther. 2018 Mar 9;9(1):59. doi: 10.1186/s13287-018-0814-4.
10
Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases.同种异体间充质干细胞移植治疗自身免疫性疾病所致肝硬化的效果
Int J Rheum Dis. 2017 Sep;20(9):1219-1226. doi: 10.1111/1756-185X.13015. Epub 2017 Feb 20.
引用本文的文献
1
The Relationship between the Number of Stem Cells and the Concentration of Stromal Cell-Derived Factor-1 with Disease Severity in Patients with Liver Cirrhosis.肝硬化患者干细胞数量及基质细胞衍生因子-1浓度与疾病严重程度的关系
Int J Hematol Oncol Stem Cell Res. 2025 Apr 1;19(2):158-164. doi: 10.18502/ijhoscr.v19i2.18553.
2
Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.探索肝硬化：治疗策略进展的见解
Int J Mol Sci. 2025 Jul 25;26(15):7226. doi: 10.3390/ijms26157226.
3
Role of cell-based therapies in digestive disorders: Obstacles and opportunities.基于细胞的疗法在消化系统疾病中的作用：障碍与机遇。
Regen Ther. 2025 Mar 4;29:1-18. doi: 10.1016/j.reth.2025.02.009. eCollection 2025 Jun.
4
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells.肝细胞衍生的肝祖细胞样细胞通过诱导肝星状细胞凋亡减轻肝硬化。
Hepatol Commun. 2025 Jan 29;9(2). doi: 10.1097/HC9.0000000000000614. eCollection 2025 Feb 1.
5
Stem cell transplantation therapy for advanced liver damage-associated neurodegenerative disorders.用于晚期肝损伤相关神经退行性疾病的干细胞移植疗法。
Int J Surg. 2024 Nov 1;110(11):6873-6882. doi: 10.1097/JS9.0000000000002001.
6
Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions.间充质干细胞在肝脏再生中的机制：见解与未来方向。
World J Stem Cells. 2024 Sep 26;16(9):842-845. doi: 10.4252/wjsc.v16.i9.842.
7
Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent.细胞摄取和间充质干细胞衍生的细胞外囊泡的体内分布依赖于蛋白质冠。
Nat Nanotechnol. 2024 Jun;19(6):846-855. doi: 10.1038/s41565-023-01585-y. Epub 2024 Feb 16.
8
Identification of Diagnostic Biomarkers for Compensatory Liver Cirrhosis Based on Gut Microbiota and Urine Metabolomics Analyses.基于肠道微生物组和尿液代谢组学分析鉴定代偿性肝硬化的诊断生物标志物。
Mol Biotechnol. 2024 Nov;66(11):3164-3181. doi: 10.1007/s12033-023-00922-9. Epub 2023 Oct 24.
9
Combinatorial Therapeutic Potential of Stem Cells and Benzimidazol Derivatives for the Reduction of Liver Fibrosis.干细胞与苯并咪唑衍生物联合治疗减轻肝纤维化的潜力
Pharmaceuticals (Basel). 2023 Feb 15;16(2):306. doi: 10.3390/ph16020306.
10
Potential advantages of genetically modified mesenchymal stem cells in the treatment of acute and chronic liver diseases.基因修饰间充质干细胞在治疗急性和慢性肝病中的潜在优势。
Stem Cell Res Ther. 2023 May 24;14(1):138. doi: 10.1186/s13287-023-03364-x.
本文引用的文献
1
Stem Cell Therapies for Treatment of Liver Disease.用于治疗肝病的干细胞疗法。
Biomedicines. 2016 Jan 6;4(1):2. doi: 10.3390/biomedicines4010002.
2
Emergency endoscopic variceal ligation in cirrhotic patients with blood clots in the stomach but no active bleeding or stigmata increases the risk of rebleeding.对胃内有血凝块但无活动性出血或血管病变征象的肝硬化患者进行急诊内镜下静脉曲张结扎术会增加再出血风险。
Clin Mol Hepatol. 2016 Dec;22(4):466-476. doi: 10.3350/cmh.2016.0063. Epub 2016 Dec 25.
3
Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis.间充质干细胞治疗肝纤维化的现状与未来展望
J Zhejiang Univ Sci B. 2016;17(11):831-841. doi: 10.1631/jzus.B1600101.
4
Epigenetic regulation of hepatic stellate cell activation and liver fibrosis.肝星状细胞激活与肝纤维化的表观遗传调控
Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1397-1408. doi: 10.1080/17474124.2016.1251309. Epub 2016 Nov 2.
5
Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?多能干细胞的临床应用：一种用于治疗肝脏疾病的替代性细胞疗法？
Transplantation. 2016 Dec;100(12):2548-2557. doi: 10.1097/TP.0000000000001426.
6
Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial.自体骨髓间充质干细胞移植治疗酒精性肝硬化：Ⅱ期临床试验。
Hepatology. 2016 Dec;64(6):2185-2197. doi: 10.1002/hep.28693. Epub 2016 Jul 30.
7
Stuttering: Clinical and research update.口吃：临床与研究进展
Can Fam Physician. 2016 Jun;62(6):479-84.
8
Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases.肝脏来源的人间充质干细胞：一种治疗肝脏疾病的新型来源。
Stem Cell Res Ther. 2016 May 12;7(1):71. doi: 10.1186/s13287-016-0330-3.
9
Reducing Hepatocyte Injury and Necrosis in Response to Paracetamol Using Noncoding RNAs.利用非编码RNA减轻对乙酰氨基酚引起的肝细胞损伤和坏死
Stem Cells Transl Med. 2016 Jun;5(6):764-72. doi: 10.5966/sctm.2015-0117. Epub 2016 Apr 7.
10
Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis.超声引导下经皮外周血单核细胞移植治疗肝硬化患者
Korean J Intern Med. 2017 Mar;32(2):261-268. doi: 10.3904/kjim.2015.267. Epub 2016 Apr 5.
Zotero 插件